RIPK1 Hign-sensitive ELISA kit (Human)

SKU: HEE640Hu

Size: 96Tests

# of Times Cited in literature: 1

Prepare Time: 2-7 days(please inquire for mutiple units)

Target Name: RIPK1

Target Full Name: Receptor Interacting Serine Threonine Kinase 1

Alternative Names: RIP; Receptor-Interacting Protein; Cell death protein RIP; Serine/threonine-protein kinase RIP

Target Species: Human

Uniprot: Q13546

Gene ID: 8737

Featured Series: HE kit

Featured Series Function: Detects protein (low-target protein, high-sensitivity)

Specificity: Reactive with Human RIPK1 / Receptor Interacting Serine Threonine Kinase 1

Method: Colormetric

Detection principle: Double-antibody Sandwich

Detection range: 0.156-10ng/mL

Sensitivity: 0.055ng/mL

Assay Time: 3h

Sample Size: 100uL

Recommended/Predicted Sample Types: Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates and other Biological Fluids

Assay Precision: Intra-Assay: CV<10%, Inter-Assay: CV<12%

Reproducibility test menthod: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level High Sensitive Receptor Interacting Serine Threonine Kinase 1 (RIPK1) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level High Sensitive Receptor Interacting Serine Threonine Kinase 1 (RIPK1) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100

Storage: 4°C for 1 month/ -20°C for long-term(One year within shelf life)

Shelf-life: 12 months

Specificity: This assay has high sensitivity and excellent specificity for detection of High Sensitive Receptor Interacting Serine Threonine Kinase 1 (RIPK1). No significant cross-reactivity or interference between High Sensitive Receptor Interacting Serine Threonine Kinase 1 (RIPK1) and analogues was observed.

Stability: The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Assay procedure summary: 1. Prepare all reagents, samples and standards; 2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C; 3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C; 4. Aspirate and wash 3 times; 5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C; 6. Aspirate and wash 5 times; 7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C; 8. Add 50µL Stop Solution. Read at 450nm immediately.

Test principle: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to High Sensitive Receptor Interacting Serine Threonine Kinase 1 (RIPK1). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to High Sensitive Receptor Interacting Serine Threonine Kinase 1 (RIPK1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain High Sensitive Receptor Interacting Serine Threonine Kinase 1 (RIPK1), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of High Sensitive Receptor Interacting Serine Threonine Kinase 1 (RIPK1) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Research Area: Enzyme & Kinase;

References Citing This Product: Persistently Elevated Plasma Levels of RIPK3, MLKL, HMGB1, and RIPK1 in COVID-19 ICU Patients